FIBRONEER-IPF: A Phase 3 Clinical Trial – Dr. Donald Zoz

This presentation, led by Dr. Donald Zoz MD, senior clinical program leader at Boehringer Ingelheim, provides some insight into FIBRONEER-IPF, a Phase 3 Clinical Trial.

The goal of FIBRONEER-IPF Phase 3 Clinical Trial is to evaluate the efficacy, safety, and tolerability of the compound BI 1015550, an investigational therapy for people with idiopathic pulmonary fibrosis (IPF).

For more information on FIBRONEER-IPF, visit or contact Boehringer Ingelheim’s Clinical Trials Support Line at 1-833-602-2368.

Additional pulmonary fibrosis clinical trial resources